Anti-MOG autoantibodies pathogenicity in children and macaques demyelinating diseases.
Anti-MOG IgG
Brain inflammation
CSF
Complement
Cytokines
Demyelination
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
30 Nov 2019
30 Nov 2019
Historique:
received:
07
03
2019
accepted:
11
11
2019
entrez:
2
12
2019
pubmed:
2
12
2019
medline:
15
5
2020
Statut:
epublish
Résumé
Autoantibodies against myelin oligodendrocyte glycoprotein (anti-MOG-Abs) occur in a majority of children with acquired demyelinating syndromes (ADS) and physiopathology is still under investigation. As cynomolgus macaques immunized with rhMOG, all develop an experimental autoimmune encephalomyelitis (EAE), we assessed relatedness between anti-MOG-Abs associated diseases in both species. The study includes 27 children followed for ADS and nine macaques with rhMOG-induced EAE. MRI lesions, cytokines in blood, and CSF at onset of ADS or EAE, as well as histopathological features of brain lesions were compared. Twelve children with anti-MOG-Abs ADS (ADS MOG+) and nine macaques with EAE, presented increased IL-6 and G-CSF in the CSF, whereas no such signature was found in 15 ADS MOG-. Furthermore, IgG and C1q were associated to myelin and phagocytic cells in brains with EAE (n = 8) and in biopsies of ADS MOG+ (n = 2) but not ADS MOG- children (n = 1). Macaque brains also revealed prephagocytic lesions with IgG and C1q depositions but no leukocyte infiltration. Children with ADS MOG+ and macaques with EAE induced with rhMOG, present a similar cytokine signature in the CSF and a comparable aspect of brain lesions indicating analogous pathophysiological processes. In EAE, prephagocytic lesions points at IgG as an initial effector of myelin attack. These results support the pertinence of modeling ADS MOG+ in non-human primates to apprehend the natural development of anti-MOG-associated disease, find markers of evolution, and above all explore the efficacy of targeted therapies to test primate-restricted molecules.
Sections du résumé
BACKGROUND
BACKGROUND
Autoantibodies against myelin oligodendrocyte glycoprotein (anti-MOG-Abs) occur in a majority of children with acquired demyelinating syndromes (ADS) and physiopathology is still under investigation. As cynomolgus macaques immunized with rhMOG, all develop an experimental autoimmune encephalomyelitis (EAE), we assessed relatedness between anti-MOG-Abs associated diseases in both species.
METHODS
METHODS
The study includes 27 children followed for ADS and nine macaques with rhMOG-induced EAE. MRI lesions, cytokines in blood, and CSF at onset of ADS or EAE, as well as histopathological features of brain lesions were compared.
RESULTS
RESULTS
Twelve children with anti-MOG-Abs ADS (ADS MOG+) and nine macaques with EAE, presented increased IL-6 and G-CSF in the CSF, whereas no such signature was found in 15 ADS MOG-. Furthermore, IgG and C1q were associated to myelin and phagocytic cells in brains with EAE (n = 8) and in biopsies of ADS MOG+ (n = 2) but not ADS MOG- children (n = 1). Macaque brains also revealed prephagocytic lesions with IgG and C1q depositions but no leukocyte infiltration.
CONCLUSIONS
CONCLUSIONS
Children with ADS MOG+ and macaques with EAE induced with rhMOG, present a similar cytokine signature in the CSF and a comparable aspect of brain lesions indicating analogous pathophysiological processes. In EAE, prephagocytic lesions points at IgG as an initial effector of myelin attack. These results support the pertinence of modeling ADS MOG+ in non-human primates to apprehend the natural development of anti-MOG-associated disease, find markers of evolution, and above all explore the efficacy of targeted therapies to test primate-restricted molecules.
Identifiants
pubmed: 31785610
doi: 10.1186/s12974-019-1637-7
pii: 10.1186/s12974-019-1637-7
pmc: PMC6884758
doi:
Substances chimiques
Autoantibodies
0
Myelin-Oligodendrocyte Glycoprotein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
244Subventions
Organisme : INSERM
ID : 00100
Organisme : Commissariat à l'Énergie Atomique et aux Énergies Alternatives
ID : 0200
Références
Arch Neurol. 2008 Nov;65(11):1527-32
pubmed: 19001173
PLoS One. 2013 Apr 18;8(4):e61835
pubmed: 23637915
J Immunol. 2010 Aug 15;185(4):2240-52
pubmed: 20624940
EBioMedicine. 2019 Sep;47:492-505
pubmed: 31492559
Vet Pathol. 2018 Jan;55(1):27-41
pubmed: 28583039
Neurol Neuroimmunol Neuroinflamm. 2015 Nov 04;2(6):e175
pubmed: 26587556
Handb Clin Neurol. 2017;145:263-283
pubmed: 28987175
J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):927-936
pubmed: 29875186
Mult Scler. 2010 Dec;16(12):1443-52
pubmed: 20739337
Ann Neurol. 2018 Aug;84(2):315-328
pubmed: 30014603
Mult Scler. 2013 Sep;19(10):1261-7
pubmed: 23572237
Clin Immunol Immunopathol. 1991 Apr;59(1):1-15
pubmed: 2019006
Neurology. 2016 Jul 12;87(2):229-31
pubmed: 27306633
JAMA Neurol. 2018 Apr 1;75(4):478-487
pubmed: 29305608
PLoS One. 2016 Feb 26;11(2):e0149411
pubmed: 26919719
J Neuroimmune Pharmacol. 2013 Dec;8(5):1251-64
pubmed: 23821341
Mult Scler. 2016 Oct;22(12):1541-1549
pubmed: 26869529
J Neuroimmunol. 2015 Dec 15;289:1-7
pubmed: 26616865
Ann Neurol. 2009 Jan;65(1):32-46
pubmed: 19194879
J Neuroinflammation. 2018 Mar 19;15(1):88
pubmed: 29554927
Nat Med. 1999 Feb;5(2):170-5
pubmed: 9930864
Neurology. 2017 Aug 29;89(9):900-908
pubmed: 28768844
Neurol Neuroimmunol Neuroinflamm. 2017 Mar 14;4(3):e335
pubmed: 28331892
Trends Mol Med. 2011 Mar;17(3):119-25
pubmed: 21251877
J Pharmacol Pharmacother. 2013 Oct;4(4):303-6
pubmed: 24250214
Ann Clin Transl Neurol. 2015 Mar;2(3):295-301
pubmed: 25815356